Central banks are signalling that higher interest rates are likely needed to tame stubborn inflation, which keeps borrowing costs elevated and funding more expensive for many risky assets. Yet that pressure has not removed the appeal of high potential growth stories; it has simply raised the bar on quality. This article looks at three biotech stocks that pair this high risk, high reward profile with balance sheets that appear more grounded than many peers.
The stocks covered below are just a small sample of the idea. The full screen surfaced 81 more biotech companies with equally compelling stories that are not discussed here. To go beyond this shortlist, head straight into the Biotech Stocks screener to identify, analyze, and focus on the highest conviction biotech opportunities.
Amgen (AMGN)
Overview:Amgen is a large biotech group that discovers, develops, manufactures and sells biologic medicines for serious diseases worldwide.
Operations:Amgen generates about US$38.9b from human therapeutics, with roughly US$27.7b from the US and US$10.9b from the rest of the world.
Market Cap:US$249.0b
For the Biotech Stocks theme, Amgen matters because it gives you exposure to a broad portfolio of commercial biologic drugs, backed by a long running research engine and a balance sheet that aims to support both new trials and ongoing shareholder payouts.
"Dividend covered about 2x by free cash flow; debt from the Horizon deal is being paid down."
What happens to that careful balance if one unseen pressure on future cash generation or capital needs shifts more than expected?
If that unknown proves material, you will want the full context. Read the full narrative for Amgen to see how dividend coverage, pipeline and debt reduction could be pulling in different directions.
Eli Lilly (LLY)
Overview:Eli Lilly develops and sells biotech-driven prescription medicines worldwide, centred on cardiometabolic biologics, peptide therapies, oncology, immunology and neuroscience treatments.
Operations:Eli Lilly generated about US$86.5b from pharmaceuticals, with roughly US$54.5b from the US and US$32.4b from international markets.
Market Cap:US$1,215.6b
Eli Lilly matters for this Biotech Stocks theme because its GLP-1 and obesity biologics give you direct exposure to blockbuster-scale biotech therapies rather than smaller, binary trial bets.
"Mounjaro (for type 2 diabetes) and Zepbound (obesity) each grew rapidly in 2024, with analysts projecting tirzepatide sales to increase through 2026, and describing Lilly's tirzepatide franchise as a key contributor to growth."
The real stress test will come if one unseen pressure on pricing or reimbursement shifts faster than today's volume-driven story assumes.
That pricing risk is only half the story, and the full narrative for Eli Lilly shows how Eli Lilly's tirzepatide franchise could keep accelerating while reimbursement pressures shift.
Johnson & Johnson (JNJ)
Overview:Johnson & Johnson is a diversified healthcare group, with its Innovative Medicine division driving biotech focused therapies across oncology, immunology and neuroscience.
Operations:The business generates about US$64.3b from Innovative Medicine and US$35.0b from MedTech, supported by broad global healthcare demand.
Market Cap:US$655.6b
For a biotech themed shortlist, Johnson & Johnson brings a mix of large scale drug research, commercial biologics and a balance sheet built for long clinical timelines.
"Johnson & Johnson anticipates accelerated growth in their portfolio and pipeline, particularly in the Innovative Medicine sector, despite the headwind from STELARA's loss of exclusivity."
The real test comes if one unseen pressure on future drug margins or capital needs bites harder than today's forecasts assume.
If that risk appears underpriced, read the full narrative for Johnson & Johnson to see how Johnson & Johnson could balance margin pressure with an accelerating pipeline story.
Seeking Fresh Alternatives Beyond Biotech?
Fresh ideas do not stay under the radar for long. Screen for the next breakout while the data still matters and sentiment has not fully caught up. Consider taking the time to review potential opportunities with care and due diligence.
-
Spot cash generative outliers before they move significantly in price by using the curated list of solid balance sheet and fundamentals (24 results) that filters for financial strength rather than story alone.
-
Review structural demand shifts early by scanning the curated 42 power grid technology and infrastructure stocks that focuses on businesses tied to long term infrastructure spending momentum.
-
Explore durable income opportunities while prices are still dropping or stalled with a hand picked 8 dividend fortresses focused on high yield payers with staying power.
This article is general in nature and was produced with the assistance of AI automation, based on data and analysis from Simply Wall St. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
